StockData

Agios Pharmaceuticals vs Akebia Therapeutics

AGIO and AKBA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGIO and AKBA compare

Agios Pharmaceuticals is the larger company, worth 16 times as much as Akebia Therapeutics ($1.8B against $111M).

Agios Pharmaceuticals grew revenue faster over the last twelve months (141% versus 7.5% for Akebia Therapeutics).

Akebia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −13.5% compared with −418% at Agios Pharmaceuticals.

Agios Pharmaceuticals scores higher on the StockData Score (12 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGIOAKBA
Size and price
Market cap$1.8B$111M
Share price$29.89$0.400
Change, 1 year−31.5%−76.0%
Change, 5 years−18.0%−85.0%
Beta (5Y)1.541.20
Employees539194
StockData Score
Total score12 (better)6
Valuation score1 (better)0
Growth score3 (better)2
Performance score22
Health score6 (better)2
Dividend score00
Valuation
P/S18.1×0.5× (better)
P/B1.7× (better)4.4×
P/FCF–2.8×
FCF yield−20.5%36.3% (better)
Fair value$27.70–
Margin of safety−7.9%–
Growth
Revenue growth (TTM)141% (better)7.5%
Revenue growth, 5Y average–−4.3%
Net income growth (TTM)−163%–
EPS growth (TTM)−163%–
Profitability
Gross margin92.0% (better)79.6%
Operating margin−467%−6.9% (better)
Net margin−418%−13.5% (better)
FCF margin−371%18.4% (better)
Return on equity−34.3% (better)−109%
Return on invested capital−759%–
Financial health
Debt / equity0.001.98 (better)
Current ratio10.22 (better)1.43
Altman Z-score11.45 (better)−5.89
Piotroski F-score17 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions111%39.7%
Held by insiders1.1%2.9%
Insider net buying, 12 months−$4.9M−$876K (better)
Short interest, % of float11.1%10.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.